Here are the 10-Q quarterly reports from Ultragenyx Pharmaceutical Inc. (RARE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RARE filings page.
Ultragenyx Pharmaceutical Inc. reported third-quarter revenue of $173 million, up 8% from $160 million a year earlier, while net loss narrowed to $118 million from $180 million. Cash, cash equivalents and marketable securities totaled $401 million as of September 30, 2026; operating activities used $337 million in cash during the first nine months.
FDA granted accelerated approval to GENGLYCOS in August and standard approval to FAYUVI in September. The GENGLYCOS priority review voucher sale closed for $210 million on October 30; the company expects $164 million in net proceeds after a $42 million NIH payment and related fees. The $203 million FAYUVI voucher sale is expected to close by year-end 2026, subject to customary closing conditions, with $185 million in expected net proceeds after a $16 million payment to a third-party licensor.
An October restructuring plan calls for an approximately 20% workforce reduction and estimated charges of approximately $25 million. The Phase 3 GTX-102 study missed its primary and key secondary endpoints, and the program is being wound down. Ultragenyx plans to terminate UX701 after it did not meet the criteria for advancement to pivotal Phase 3.
Ultragenyx Pharmaceutical Inc. reported Q2 2026 revenue of $214 million, up 28% from Q2 2025, driven by higher Crysvita product and royalty revenue and expanding sales of Dojolvi, Evkeeza, and Mepsevii. Product sales were $112 million and Crysvita royalty revenue was $102 million in the quarter.
Net loss for Q2 2026 narrowed to $92 million (basic and diluted net loss per share $0.90) from $115 million a year earlier as revenue growth outpaced operating expense increases. For the first six months of 2026, revenue was $350 million and net loss was $277 million. Cash, cash equivalents and marketable securities totaled $436 million as of June 30, 2026, with $294 million used in operating activities in the first half. Liabilities for sales of future Crysvita royalties were $1.20 billion, contributing to a stockholders’ deficit of $291 million. A February 2026 restructuring reduced headcount by about 10% and generated $30 million in charges, all settled by June 30, 2026. Key near-term catalysts include FDA Priority Review decisions for DTX401 (PDUFA August 23, 2026) and UX111 (PDUFA September 19, 2026), and pivotal GTX-102 data expected in late 2026; management states expectations for profitability in 2027.
Ultragenyx Pharmaceutical Inc. reported a net loss of $185 million for the quarter ended March 31, 2026, on $136 million in total revenues, down 2% year over year. Product sales were $89 million, led by Crysvita at $46 million, while Crysvita royalty revenue contributed $47 million.
Research and development expenses rose to $187 million, driven by manufacturing and late-stage work on gene therapies DTX401 and UX111 and biologic programs GTX‑102 and UX143. Selling, general and administrative costs were stable at $88 million.
The company booked $30 million of restructuring charges tied to a February 2026 plan that cut its workforce by about 10% and curtailed certain activities, including UX143 manufacturing. Cash, cash equivalents and marketable securities totaled $534 million, while liabilities for sales of future Crysvita royalties reached $1.2 billion.
Ultragenyx Pharmaceutical (RARE) reported higher Q3 revenue and a wider loss. Total revenues were $159.9 million, up from $139.5 million a year ago, driven by product sales of $95.0 million and Crysvita royalties of $64.9 million. Crysvita revenue across product sales and royalties reached $111.9 million.
The company posted a net loss of $180.4 million (basic and diluted loss per share $1.81) versus a loss of $133.5 million last year, reflecting increased R&D and SG&A. For the first nine months, revenue was $465.7 million and net loss was $446.4 million.
Cash and cash equivalents were $202.5 million, with $244.8 million of marketable debt securities (current and non‑current). Total assets were $1.19 billion against total liabilities of $1.17 billion, leaving stockholders’ equity at $9.2 million. Liabilities for sales of future royalties totaled $829.3 million. As of October 30, 2025, 96,477,569 shares of common stock were outstanding.